Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
51 hedge funds and large institutions have $197M invested in Galera Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
16% more capital invested
Capital invested by funds: $170M → $197M (+$27.3M)
16% more funds holding
Funds holding: 44 → 51 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$9.47M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$2.64M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$1.95M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 5 |
BlackRock
New York
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.46M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.92M |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$405K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$73.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$56.7K |
GRTX Hedge Fund Activity: Q4 2020 in Review
51 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q4 2020, worth a combined $197M — up 16% from $170M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GRTX positions and 1 closed out — a net gain of 7 holders — while 20 added to existing stakes and 8 trimmed.
The largest buyer was VR Adviser, adding an estimated $9.47M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.46M sold.
- 51 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q4 2020, up from 44 in Q3 2020.
- Funds reported $197M of Galera Therapeutics, Inc. Common Stock stock for Q4 2020, up 16% quarter-over-quarter.
- 8 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q4 2020 and 1 closed out, a net change of +7 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q4 2020 was VR Adviser, an estimated $9.47M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $7.46M sold.
Based on aggregated 13F filings for Q4 2020.